Firm News
Wiggin and Dana Client Notable Labs Announces Merger With VBL Therapeutics
Wiggin and Dana recently representedย Notable Labs, Inc. (Notable), a clinical stage therapeutics platform company developing predictive precision medicines for cancer patients, in its merger with VBL Therapeutics (Nasdaq: VBLT) and associated financing transaction. Through the merger, the combined companyโs efforts will now be on the advancement of Notableโs proprietary Predictive Precision Medicines Platform (โPPMPโ) and therapeutic pipeline focused on cancer patients with high unmet medical needs.
On October 17, shares of the combined company, renamed Notable Labs, Ltd., will begin trading on NASDAQ, under the new ticker symbol โNTBLโ. Under the terms of the merger agreement, Notable stockholders now own about 75% and VBL shareholders own roughly 25% of the combined company.
$10.3 million in new funding was also invested prior to closing of the merger by Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund.
The Wiggin deal team consisted ofย Evan Kipperman,ย Michael Grundei, James Greifzu, Elishama Rudolph, Patti Melick..
To learn more and read the official press release, please click here.
